Direct real-time PCR examination for Mycobacterium tuberculosis in respiratory samples can be cost effective

Bryan Joseph Renton, Patricia Denise Morrell, Richard Peter Davidson Cooke, Peter David Owen Davies

.

DOI: 10.4236/health.2009.12011                

Abstract

Aim: To assess whether the use of direct real- time polymerase chain reaction (PCR) on smear-positive sputa can be cost-effective, by speciating mycobacteria earlier than current methods and thereby preventing unnecessary screening tests as part of the contact tracing process. Methods: A retrospective study of all patients with smear-positive sputa in a Liverpool teach-ing hospital between 2004 and 2007. All the PCRs performed on these patients were re-viewed and compared them with their myco-bacterial culture results. Unit costs for PCR, chest X-ray (CXR), tuberculin skin test (TST), interferon-gamma (IFN-γ) and medical/nursing time were conservatively estimated at £50, £11, £10, £40 and £30 respectively. The total PCR costs were compared with the costs of unnec-essary follow up of patients, negative for My-cobacterium tuberculosis (MTB) by PCR, sub-sequently confirmed to be MTB culture nega-tive. Results: 203 smear-positive patients under-went direct PCR testing. 126 (62%) patients grew Mycobacterium tuberculosis (MTB), 74 (37%) had environmental mycobacterial infection (EMI) and 3 (1%) were culture negative. Of the 126 patients’ culture positive MTB patients, 123 were PCR positive and 3 PCR negative. Of the 77 pa-tients that were culture negative for MTB, 75 were PCR negative and 2 PCR positive The sensitivity, specificity, positive and negative predictive values for direct PCR versus MTB culture were 98%, 96%, 98% and 97% respec-tively. Total costs of all PCRs performed amounted to £10,150. The cost of contact pro-cedures for PCR-negative and MTB culture- negative index cases was estimated at £19,650. This equated to a total saving of £9,500 in contact tracing costs. Conclusions: Direct PCR examination testing of smear-positive patients can be cost-effective in areas where there is a high incidence of EMI.

Keywords

Tuberculosis; PCR and Cost Effective

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	CG33 Tuberculosis – National Institute of Clinical Ex-cellent (NICE) guidelines. March 2006.
[2]	Corless, J.A., Stockton, P.A., Davies, P.D. (2000) Myco-bacterial culture results of smear-positive patients with suspected pulmonary tuberculosis in Britain. Eur Respir J, 16: 976-9.
[3]	National Collaborating Centre for Chronic Conditions: clinical diagnosis and management of tuberculosis and measures for its prevention and control. (2006). London, Royal College of Physicians.
[4]	Cramer, S.O., Matinmehr, F, Hillemann, D. (2004) Fast and sensitive detection of the Mycobacterium tuberculo-sis complex by real-time PCR, Clinical Microbiology and Infection, 10(3), 418.
[5]	Drobniewski, F.A., Watterson, S.A., Wilson, S.M., Harris, G.A. (2000) A clinical, microbiological and economic analysis of a national service for the rapid molecular di-agnosis of tuberculosis and rifampicin resistance in My-cobacterium tuberculosis. J Med Microbiol, 49:271-8.
[6]	Dowdy, D.W., Maters, A., Parrish, N., Beyrer, C., Dorman, S.E. (2003) Cost-effectiveness analysis of the Gen-Probe amplified Mycobacterium tuberculosis direct test as used routinely on smear-positive respiratory specimens. J Clin Microbiol, 41(3), 948-953.
[7]	van Cleeff, M., Kivihya-Ndugga, L., Githui, W., Ng’ang’a L., Kibuga, D., Odhiambo, J., et al. (2005) Cost-effectiveness of polymerase chain reaction versus Ziehl-Neelsen smear microscopy for diagnosis of tuber-culosis in Kenya. Int J Tuberc Lung Dis, 9:877-83.
[8]	Zalekis, R. (2005) Side-effects of Tuberculosis treatment. Breathe, 2(1), 69-73.
[9]	Piersimoni, C. and Scarparo, C. (2003) Minre-view–Relevance of commercial amplification methods for direct detection of Mycobacterium tuberculosis com-plex in clinical samples. J Clin Microbiol, 41(12), 5355- 5365.
[10]	Taegtmeyer, M., Beeching, N.J., Scott, J., Seddon, K., Jamieson, S., Squire, S.B., Mwandumba, H.C., Miller, A.R.O., Davies, P.D.O., Parry, C.M. ( 2007) The Clinical impact of nucleic acid amplification tests on the diagno-sis and management of tuberculosis in a British hospital. Thorax Online.
[11]	Griffith, D.E., Aksamit, T., Barbara, A., et al. (2007) American thoracic society guidelines: Diagnosis, treat-ment and prevention of nontuberculous mycobacterial diseases. Am J Resp and Crit Care Med, 175, 367-417.